{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T04:36:57Z","timestamp":1759207017144},"reference-count":58,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IRDR"],"published-print":{"date-parts":[[2023,5,31]]},"DOI":"10.5582\/irdr.2023.01003","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T22:12:31Z","timestamp":1684879951000},"page":"88-96","source":"Crossref","is-referenced-by-count":3,"title":["Health-related quality of life (HRQoL) and psychological impact of the COVID-19 pandemic on patients with myasthenia gravis"],"prefix":"10.5582","volume":"12","author":[{"given":"Irune","family":"Garc\u00eda","sequence":"first","affiliation":[{"name":"Department of Psychology, Faculty of Health Sciences, University of Deusto, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar","family":"Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Department of Psychology, Faculty of Health Sciences, University of Deusto, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Francisco","family":"L\u00f3pez-Paz","sequence":"additional","affiliation":[{"name":"Department of Psychology, Faculty of Health Sciences, University of Deusto, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Salgueiro","sequence":"additional","affiliation":[{"name":"Department of Clinical and Health Psychology and Research Methodology, Faculty of Psychology, University of the Basque Country UPV\/ EHU. Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia Aurora","family":"Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Department of Psychology, Faculty of Health Sciences, University of Deusto, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janire","family":"Zorita","sequence":"additional","affiliation":[{"name":"Department of Psychology, Faculty of Health Sciences, University of Deusto, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maddalen","family":"Garc\u00eda-Sanchoyerto","sequence":"additional","affiliation":[{"name":"Department of Psychology, Faculty of Health Sciences, University of Deusto, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imanol","family":"Amayra","sequence":"additional","affiliation":[{"name":"Department of Psychology, Faculty of Health Sciences, University of Deusto, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Auvin S, Irwin J, Abi-Aad P, Battersby A. The problem of rarity: Estimation of prevalence in rare disease. Value Health. 2018; 21:501-507.","DOI":"10.1016\/j.jval.2018.03.002"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Nguengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, Murphy D, Le Cam Y, Rath A. Estimating cumulative point prevalence of rare diseases: Analysis of the Orphanet database. Eur J Hum Genet. 2020; 28:165-173.","DOI":"10.1038\/s41431-019-0508-0"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Whicher D, Philbin S, Aronson N. An overview of the impact of rare disease characteristics on research methodology. Orphanet J Rare Dis. 2018;13:14.","DOI":"10.1186\/s13023-017-0755-5"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Lenderking WR, Anatchkova M, Pokrzywinski R, Skalicky A, Martin ML, Gelhorn H. Measuring health-related quality of life in patients with rare disease. J Patient Rep Outcomes. 2021; 5:61.","DOI":"10.1186\/s41687-021-00336-8"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM. Myasthenia gravis. Nat Rev Dis Primers. 2019; 5:30.","DOI":"10.1038\/s41572-019-0079-y"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Koneczny I, Herbst R. Myasthenia gravis: Pathogenic effects of autoantibodies on neuromuscular architecture. Cells. 2019; 8:671.","DOI":"10.3390\/cells8070671"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol. 2010; 10:46.","DOI":"10.1186\/1471-2377-10-46"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Vitturi BK, Kim AIH, Mitre LP, Pellegrinelli A, Valerio BCO. Social, professional and neuropsychiatric outcomes in patients with myasthenia gravis. Neurol Sci. 2021; 42:167-173.","DOI":"10.1007\/s10072-020-04528-w"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Jeong A, Min J, Kang YK, Kim J, Choi M, Seok JM, Kim BJ. Factors associated with quality of life of people with Myasthenia Gravis. PLoS One. 2018; 13:e0206754.","DOI":"10.1371\/journal.pone.0206754"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Mart\u00ednez O, Amayra I, L\u00f3pez-Paz JF, L\u00e1zaro E, Caballero P, Garc\u00eda I, Rodr\u00edguez AA, Garc\u00eda M, Luna PM, P\u00e9rez-Nu\u00f1ez P, Barrera J, Passi N, Berrocoso S, P\u00e9rez M, Al-Rashaida M. Effects of teleassistance on the quality of life of people with rare neuromuscular diseases according to their degree of disability. Front Psychol. 2021; 12:637413.","DOI":"10.3389\/fpsyg.2021.637413"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. S\u00e1nchez-Garc\u00eda JC, Cort\u00e9s-Mart\u00edn J, Rodr\u00edguez-Blanque R, Mar\u00edn-Jim\u00e9nez AE, Montiel-Troya M, D\u00edaz-Rodr\u00edguez L. Depression and anxiety in patients with rare diseases during the COVID-19 pandemic. Int J Environ Res. 2021; 18:3234.","DOI":"10.3390\/ijerph18063234"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Stankovic M, Peric S, Stojiljkovic Tamas O, Stankovic T, Nikolic A, Lavrnic D, Basta I. Quality of life in patients with MuSK positive myasthenia gravis. Acta Neurol Belg. 2018; 118:423-427.","DOI":"10.1007\/s13760-018-0915-y"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Serafini G, Parmigiani B, Amerio A, Aguglia A, Sher L, Amore M. The psychological impact of COVID-19 on the mental health in the general population. QJM. 2020; 113:531-537.","DOI":"10.1093\/qjmed\/hcaa201"},{"key":"14","unstructured":"14. Agencia Estatal Bolet\u00edn Oficial del Estado. Ley 2\/2021, de 29 de marzo, de medidas urgentes de prevenci\u00f3n, contenci\u00f3n y coordinaci\u00f3n para hacer frente a la crisis sanitaria ocasionada por el COVID-19. <i>https:\/\/www.boe.es\/buscar\/act.php?id=BOE-A-2021-4908 <\/i>(in Spanish)"},{"key":"15","unstructured":"15. World Health Organization. Mental health and COVID-19: Early evidence of the pandemic&apos;s impact: Scientific brief, 2 March 2022. <i>https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-Sci_Brief-Mental_health-2022.1<\/i> (accessed May 9, 2023)"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Fan FC, Zhang SY, Cheng Y. Incidence of psychological illness after coronavirus outbreak: A meta-analysis study. J Epidemiol Community Health. 2021; 75:836-842.","DOI":"10.1136\/jech-2020-215927"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Krishnamoorthy Y, Nagarajan R, Saya GK, Menon V. Prevalence of psychological morbidities among general population, healthcare workers and COVID-19 patients amidst the COVID-19 pandemic: A systematic review and meta-analysis. Psychiatry Res. 2020; 293:113382.","DOI":"10.1016\/j.psychres.2020.113382"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Liu X, Zhu M, Zhang R, Zhang J, Zhang C, Liu P, Feng Z, Chen Z. Public mental health problems during COVID-19 pandemic: A large-scale meta-analysis of the evidence. Transl Psychiatry. 2021; 11:384.","DOI":"10.1038\/s41398-021-01501-9"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Gonz\u00e1lez-Sanguino C, Aus\u00edn B, Castellanos M\u00c1, Saiz J, L\u00f3pez-G\u00f3mez A, Ugidos C, Mu\u00f1oz M. Mental health consequences of the coronavirus 2020 pandemic (COVID-19) in Spain. A longitudinal study. Front Psychiatry. 2020; 11:565474.","DOI":"10.3389\/fpsyt.2020.565474"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. M\u00fcller F, R\u00f6hr S, Reininghaus U, Riedel-Heller SG. Social isolation and loneliness during COVID-19 lockdown: Associations with depressive symptoms in the German old-age population. Int J Environ Res Public Health. 2021; 18:3615.","DOI":"10.3390\/ijerph18073615"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Halley MC, Stanley T, Maturi J, Goldenberg AJ, Bernstein JA, Wheeler MT, Tabor HK. &quot;It seems like COVID-19 now is the only disease present on Earth&quot;: Living with a rare or undiagnosed disease during the COVID-19 pandemic. Genet Med. 2021; 23:837-844.","DOI":"10.1038\/s41436-020-01069-7"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Narayanan P, Nair S, Balwani M, Malinis M, Mistry P. The clinical spectrum of SARS-CoV-2 infection in Gaucher disease: Effect of both a pandemic and a rare disease that disrupts the immune system. Mol Genet Metab. 2022; 135:115-121.","DOI":"10.1016\/j.ymgme.2021.08.004"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Angelini C, Siciliano G. Neuromuscular diseases and Covid-19: Advices from scientific societies and early observations in Italy. Eur J Transl Myol. 2020; 30:9032.","DOI":"10.4081\/ejtm.2020.9032"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Bertran Recasens B, Rubio MA. Neuromuscular diseases care in the era of COVID-19. Front Neurol. 2020; 11:588929.","DOI":"10.3389\/fneur.2020.588929"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Camelo-Filho AE, Silva A, Estephan EP, Zambon AA, Mendon\u00e7a RH, Souza PV, Pinto WB, Oliveira AS, Dangoni-Filho I, Pouza AF, Valerio BC, Zanoteli E. Myasthenia gravis and COVID-19: clinical characteristics and outcomes. Front Neurol. 2020; 11:1053.","DOI":"10.3389\/fneur.2020.01053"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Dewanjee S, Vallamkondu J, Kalra RS, Puvvada N, Kandimalla R, Reddy PH. Emerging COVID-19 neurological manifestations: present outlook and potential neurological challenges in COVID-19 pandemic. Mol Neurobiol. 2021; 58:4694-4715.","DOI":"10.1007\/s12035-021-02450-6"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Guidon AC, Amato AA. COVID-19 and neuromuscular disorders. Neurology. 2020; 94:959-969.","DOI":"10.1212\/WNL.0000000000009566"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. International MG\/COVID-19 Working Group; Jacob S, Muppidi S, Guidon A, Guptill J, Hehir M, Howard JF Jr, Illa I, Mantegazza R, Murai H, Utsugisawa K, Vissing J, Wiendl H, Nowak RJ. Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. J Neurol Sci. 2020; 412:116803.","DOI":"10.1016\/j.jns.2020.116803"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Jakubikova M, T\u00fdblov\u00e1 M, Tesa\u0159 A, Hor\u00e1kov\u00e1 M, Vla\u017en\u00e1 D, Ry\u0161\u00e1nkov\u00e1 I, Nov\u00e1kov\u00e1 I, Dole\u010dkov\u00e1 K, Du\u0161ek P, Pi\u0165ha J, Voh\u00e1\u0148ka S, Bedna\u0159\u00edk J. Predictive factors for a severe course of COVID\u201019 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival. Eur J Neurol. 2021; 28:3418-3425.","DOI":"10.1111\/ene.14951"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Li Y, Emmett CD, Cobbaert M, Sanders DB, Juel VC, Hobson\u2010Webb LD, Massey JM, Gable KL, Raja SM, Gonzalez NL, Guptill JT. Knowledge and perceptions of the COVID\u201019 pandemic among patients with myasthenia gravis. Muscle Nerve. 2021; 63:357-364.","DOI":"10.1002\/mus.27130"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Kalita J, Tripathi A, Dongre N, Misra UK. Impact of COVID-19 pandemic and lockdown in a cohort of myasthenia gravis patients in India. Clin Neurol Neurosurg. 2021; 202:106488.","DOI":"10.1016\/j.clineuro.2021.106488"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Chowdhury SF, Sium SMA, Anwar S. Research and management of rare diseases in the COVID-19 pandemic era: Challenges and countermeasures. Front Public Health. 2021; 9:640282.","DOI":"10.3389\/fpubh.2021.640282"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Caparr\u00f3s Boix\u00e9s G, Su\u00f1er Soler R, Juviny\u00e1 Canal D, Reig Garcia G. The impact of the COVID-19 pandemic on the control of chronic diseases in primary care. Aten Primaria. 2022; 54:102233. (in Spanish)","DOI":"10.1016\/j.aprim.2021.102233"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Coma E, Mora N, M\u00e9ndez L, <i>et al<\/i>. Primary care in the time of COVID-19: Monitoring the effect of the pandemic and the lockdown measures on 34 quality of care indicators calculated for 288 primary care practices covering about 6 million people in Catalonia. BMC Fam Pract. 2020; 21:208.","DOI":"10.1186\/s12875-020-01278-8"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Chung CCY, Ng YNC, Jain R, Chung BHY. A thematic study: Impact of COVID-19 pandemic on rare disease organisations and patients across ten jurisdictions in the Asia Pacific region. Orphanet J Rare Dis. 2021; 16:119.","DOI":"10.1186\/s13023-021-01766-9"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992; 30:473-483.","DOI":"10.1097\/00005650-199206000-00002"},{"key":"37","unstructured":"37. Alonso J, Prieto L, Anto JM. The Spanish version of the SF-36 Health Survey (the SF-36 health questionnaire): An instrument for measuring clinical results. Med Clin (Barc). 1995; 104:771-776. (in Spanish)"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Alonso J, Prieto L, Ferrer M, Vilagut G, Broquetas JM, Roca J, Batlle JS, Ant\u00f3 JM. Testing the measurement properties of the Spanish version of the SF-36 Health Survey among male patients with chronic obstructive pulmonary disease. J Clin Epidemiol. 1998; 51:1087-1094.","DOI":"10.1016\/S0895-4356(98)00100-0"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983; 67:361-370.","DOI":"10.1111\/j.1600-0447.1983.tb09716.x"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Herrero MJ, Blanch J, Peri JM, De Pablo J, Pintor L, Bulbena A. A validation study of the hospital anxiety and depression scale (HADS) in a Spanish population. Gen Hosp Psychiatry. 2003; 25:277-283.","DOI":"10.1016\/S0163-8343(03)00043-4"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Russell D, Peplau LA, Cutrona CE. The revised UCLA Loneliness Scale: concurrent and discriminant validity evidence. J Pers Soc Psychol. 1980; 39: 472-480.","DOI":"10.1037\/0022-3514.39.3.472"},{"key":"42","unstructured":"42. V\u00e1zquez Morej\u00f3n AJ, Jim\u00e9nez Garc\u00eda-B\u00f3veda R. RULS: Escala de soledad UCLA revisada. Fiabilidad y validez de una versi\u00f3n espa\u00f1ola. J Health Psychol. 1994; 6:45-54. (in Spanish)"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Ahorsu DK, Lin CY, Imani V, Saffari M, Griffiths MD, Pakpour AH. The Fear of COVID-19 Scale: Development and Initial Validation. Int J Ment Health Addict. 2022; 20:1537-1545.","DOI":"10.1007\/s11469-020-00270-8"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Mart\u00ednez-Lorca M, Mart\u00ednez-Lorca A, Criado-\u00c1lvarez JJ, Armesilla MDC, Latorre JM. The fear of COVID-19 scale: Validation in spanish university students. Psychiatry Res. 2020; 293:113350.","DOI":"10.1016\/j.psychres.2020.113350"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Piqueras JA, Gomez-Gomez M, Marzo JC, Gomez-Mir P, Falco R, Valenzuela B. Validation of the Spanish version of <i>fear of COVID-19 scale<\/i>: Its association with acute stress and coping. Int J Ment Health Addict. 2023; 21:711-728.","DOI":"10.1007\/s11469-021-00615-x"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Budu MO, Rugel EJ, Nocos R, Teo K, Rangarajan S, Lear SA. Psychological impact of COVID-19 on people with pre-existing chronic disease. Int J Environ Res. 2021; 18:5972.","DOI":"10.3390\/ijerph18115972"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Cankurtaran D, Tezel N, Ercan B, Yildiz SY, Akyuz EU. The effects of COVID-19 fear and anxiety on symptom severity, sleep quality, and mood in patients with fibromyalgia: A pilot study. Adv Rheumatol. 2021; 61:41.","DOI":"10.1186\/s42358-021-00200-9"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Jones SM, Gwathmey KG, Burns TM. Quality of life measures for myasthenia gravis and evaluation of non\u2010motor symptoms. Clin Exp Neuroimmunol. 2015; 6:32-39.","DOI":"10.1111\/cen3.12174"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Berrih-Aknin S, Claeys KG, Law N, Mantegazza R, Murai H, Sacc\u00e0 F, Dewilde S, Janssen MF, Bagshaw E, Kousoulakou H, Larkin M, Beauchamp J, Leighton T, Paci S. Patient-reportedimpact of myasthenia gravis in the real world: protocol for a digital observational study (MyRealWorld MG). BMJ Open. 2021; 11:e048198.","DOI":"10.1136\/bmjopen-2020-048198"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Braz NFT, Rocha NP, Vieira \u00c9LM, Barbosa IG, Gomez RS, Kakehasi AM, Teixeira AL. Muscle strength and psychiatric symptoms influence health-related quality of life in patients with myasthenia gravis. J Clin Neurosci. 2018; 50:41-44.","DOI":"10.1016\/j.jocn.2018.01.011"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Ruiter AM, Verschuuren JJGM, Tannemaat MR. Prevalence and associated factors of fatigue in autoimmune myasthenia gravis. Neuromuscul Disord. 2021; 31:612-621.","DOI":"10.1016\/j.nmd.2021.04.002"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Griffin SC, Williams AB, Ravyts SG, Mladen SN, Rybarczyk BD. Loneliness and sleep: A systematic review and meta-analysis. Health Psychol Open. 2020; 7:2055102920913235.","DOI":"10.1177\/2055102920913235"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Hansen T, Nilsen TS, Yu B, Knapstad M, Skogen JC, Vedaa \u00d8, Nes RB. Locked and lonely? A longitudinal assessment of loneliness before and during the COVID-19 pandemic in Norway. Scand J Public Health. 2021; 49:766-773.","DOI":"10.1177\/1403494821993711"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Smith KJ, Gavey S, RIddell NE, Kontari P, Victor C. The association between loneliness, social isolation and inflammation: A systematic review and meta-analysis. Neurosci Biobehav Rev. 2020; 112:519-541.","DOI":"10.1016\/j.neubiorev.2020.02.002"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Pfefferbaum B, North CS. Mental health and the Covid-19 pandemic. N Engl J Med. 2020; 383:510-512.","DOI":"10.1056\/NEJMp2008017"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Ricciardi D, Casagrande S, Iodice F, Orlando B, Trojsi F, Cirillo G, Clerico M, Bozzali M, Leocani L, Abbadessa G, Miele G, Tedeschi G, Bonavita S, Lavorgna L; Digital Technologies, Web, Social Media Study Group of the Italian Society of Neurology. Myasthenia gravis and telemedicine: A lesson from COVID-19 pandemic. Neurol Sci. 2021; 42:4889-4892.","DOI":"10.1007\/s10072-021-05566-8"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Pai M, Yeung CHT, Akl EA, Darzi A, Hillis C, Legault K, Meerpohl JJ, Santesso N, Taruscio D, Verhovsek M, Sch\u00fcnemann HJ, Iorio A. Strategies for eliciting and synthesizing evidence for guidelines in rare diseases. BMC Med Res Methodol. 2019; 19:67.","DOI":"10.1186\/s12874-019-0713-0"},{"key":"58","unstructured":"58. American Psychological Association. Guidance on psychological tele-assessment during the COVID-19 crisis. <i>https:\/\/www.apaservices.org\/practice\/reimbursement\/health-codes\/testing\/tele-assessment-covid-19<\/i> (accessed May 9, 2023)"}],"container-title":["Intractable &amp; Rare Diseases Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/12\/2\/12_2023.01003\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T04:59:39Z","timestamp":1686977979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/12\/2\/12_2023.01003\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,31]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.5582\/irdr.2023.01003","relation":{},"ISSN":["2186-361X","2186-3644"],"issn-type":[{"value":"2186-361X","type":"electronic"},{"value":"2186-3644","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,31]]},"article-number":"2023.01003"}}